key: cord-0429843-6ybcxfuv
authors: Yu, Hanna; Khokhlatchev, Andrei V; Chew, Claude; Illendula, Anuradha; Conaway, Mark; Dryden, Kelly; Maeda, Denicar Lina Nascimento Fabris; Rajasekaran, Vignesh; Kester, Mark; Zeichner, Steven L.
title: Minicells from Highly Genome Reduced Escherichia coli: Cytoplasmic and Surface Expression of Recombinant Proteins and Incorporation in the Minicells
date: 2021-06-16
journal: bioRxiv
DOI: 10.1101/2021.06.16.448719
sha: aa513087231d3869719304547ed660487f29a241
doc_id: 429843
cord_uid: 6ybcxfuv

Minicells, small cells lacking a chromosome, produced by bacteria with mutated min genes, which control cell division septum placement, have many potential uses. Minicells have contributed to basic bacterial physiology studies and can enable new biotechnological applications, including drug delivery and vaccines. Genome-reduced (GR) bacteria are another informative area of investigation. Investigators identified that with even almost 30% of the E. coli genome deleted, the bacteria still live. In biotechnology and synthetic biology, GR bacteria offer certain advantages. With GR bacteria, more recombinant genes can be placed into GR chromosomes and fewer cell resources are devoted to purposes apart from biotechnological goals. Here, we show that these two technologies can be combined: min mutants can be made in GR E. coli. The minCminD mutant GR E. coli produce minicells that concentrate engineered recombinant proteins within these spherical delivery systems. We expressed recombinant GFP protein in the cytoplasm of GR bacteria and showed that it is concentrated within the minicells. We also expressed proteins on the surfaces of minicells made from GR bacteria using a recombinant Gram-negative AIDA-I autotransporter expression cassette. As some autotransporters, like AIDA-I, are concentrated at the bacterial poles, where minicells bud, and because the surface-to-volume ratio of the small minicells is higher than bacteria, recombinant proteins expressed on surfaces of the GR bacteria are concentrated on the minicells. Minicells made from GR bacteria can enable useful biotechnological innovations, such as drug delivery vehicles and vaccine immunogens.

Investigators have studied the minimum complement of genes required for a living bacteria. Some investigators have taken an additive, synthetic approach 1-3 . Other 65 investigators have taken a subtractive approach, in which they make serial deletions in the bacterial chromosome. The Tokyo Metropolitan University Group, for example 4, 5 , showed that they could delete up to 29.7% of the E. coli genome and still have viable bacteria. However, the doubling time is about twice as long for the highly deleted strains than for the wild type and the highly deleted strains exhibit altered morphology. Such 70 studies offer insights into the minimal complement of genes needed for a viable bacterial cell. GR bacteria also present useful biotechnological applications. Eliminating genes not essential for growth can minimize diversion of energy and substrates for biotechnologically non-productive purposes or make additional chromosome capacity available for engineering goals. Eliminating genes involved in formation of bacterial 75 structures may enable more effective studies of remaining structures. If animals are exposed to antigen over-expressing bacteria with many fewer functional genes, they have the potential to be less reactogenic.

Minicells (reviewed in 6 ) were described more than 50 years ago 7 . In E. coli, proteins of the Min system, MinC, MinD, and MinE control the placement of the Z-ring in 80 the middle of the bacterial cell by preventing assembly of the FtsZ complex at locations other than the middle of the cell. In wild type cells, these proteins promote cell division into approximately equal size daughter cells, and prevent formation of daughter cells lacking a bacterial chromosome. In min mutant cells, the Z-ring can form not only in the middle of the cell about to undergo division, but also toward one of the poles. When the 85 Z-ring forms close to a pole, cell division yields a large cell with copies of the bacterial chromosome and a minicell lacking the chromosome. Mother cells containing bacterial chromosomes continue to divide, enabling ongoing minicell production. While daughter minicells are incapable of further reproduction, they remain metabolically and biosynthetically active. Minicells can be produced in quantity, using differential 90 centrifugation and filtration approaches 8, 9 . Minicells have proved useful, both for the study of basic biological processes and for biotechnological uses. Minicells have been helpful in the study of bacterial processes and machinery, such as the flagellum and Type III secretion systems 10, 11 since studies employing cryo-electron tomography are easier. Minicells also played an important part 95 in studies of bacteriophage physiology [12] [13] [14] . Biotechnological applications include the use of minicells to encapsulate drugs 9 , and have been proposed as potential vaccine antigen delivery vehicles 15, 16 .

It may be useful to place recombinant proteins on the surfaces and make bacterial derivatives with enriched concentrations of recombinant surface proteins. 100

Gram-negative autotransporters (autodisplay proteins, Type V secretion systems) (reviewed in [17] [18] [19] ) enable the placement of large numbers of recombinant proteins on the bacterial surface. Autotransporters have three domains: an N-terminal signal sequence that helps mediate transfer of the protein across the inner membrane via a Sec translocon mechanism, a central passenger protein domain that includes the 105 effector portion of the protein, and a C-terminal β-barrel domain that intercalates into the outer membrane to form a pore-like structure, aided by the β-barrel assembly machinery (Bam) complex 20 . The passenger domain transits out to the extracellular environment through the pore of the β-barrel. The β-barrel may exhibit chaperonin-like activity, aiding in the correct formation of passenger protein tertiary structure during transit to the 110 extracellular environment. Subject to some limitations, for example an intolerance for disulfide bonds and certain size limitations, DNA sequences encoding heterologous proteins can replace native passenger protein coding sequence, so that autotransporters can be used to place heterologous recombinant proteins on the surface of the bacteria, anchored into the outer membrane by the β-barrel. Recombinant 115 autotransporters have been used to place a variety of biotechnologically useful molecules on the surfaces of bacteria, including enzymes, biosensors, and vaccine antigens. However, no clinically useful vaccines have yet been produced using autotransporter expression systems, perhaps because the first vaccine applications were attempted using live bacteria as vaccine vectors with attendant safety concerns 17, 120 18 , or the antigens expressed on the surfaces of the bacteria were insufficiently immunogenic.

At least some autotransporters preferentially accumulate at the bacterial poles 21 , so it may be anticipated that recombinant proteins expressed on the surfaces of bacteria by means of the autotransporters will be enriched in minicells, since the 125 minicells bud off from the poles. Combining substantial genome reduction with expression of recombinant proteins on the bacterial surface using autotransporters in combination with budding of the minicells from the bacterial poles would be expected to additionally enrich the relative amounts of the recombinant proteins on the surface of the minicells compared to expression of a protein in the cytoplasm or on the surface of 130 non-genome reduced whole bacterial cells.

While both genome-reduced bacteria and minicells hold significant promise for a variety of biotechnological purposes, to our knowledge, these two technologies have not been previously combined. Here, we show that the minC and minD genes of highly GR E. coli can be deleted and that the resulting mutant bacteria are viable and 135 biotechnologically functional.

Production of the minC/minD mutations in genome reduced E. coli strains. To explore whether it is possible to mutate the minC and minD genes of genome reduced 140 bacteria and then make minicells from those mutant bacteria we obtained the comprehensive collection of genome deletions produced by the Tokyo Metropolitan University Group 4, 5 from a derivative of E. coli MG1655. We focused on the following strains: ME 5000 (parental, non-deleted strain), ME 5010 (2.4% deleted), ME 5119 (15.8% deleted) and ME 5125 (29.7% deleted, the most deleted strain in the collection). 145

These strains, while they are alive, grow with a significantly reduced doubling time (~40 min for the 29.7% deleted strain), and altered morphology. We used lambda Red recombineering 22 to delete the minC and minD genes. We screened for the presence of the inserted marker, and confirmed the mutation by colony PCR and sequencing. We then cured the strain of kanamycin resistance by recombination with a derivative of 150 pCP20 22, 23 and verified the removal of the kanamycin resistance gene phenotypically, confirmed removal with sequencing, and reconfirmed the minicell production phenotype as described below. To examine expression in the minicells made from the genome reduced bacteria, we used a plasmid, pMP2463 that expresses GFP, and we commissioned the synthesis of a plasmid, pRAIDA2 (FIG 1) , that includes an AIDA-I-155 based autotransporter expression cassette 24, 25 . In its parental form, pRAIDA2 has an influenza HA immunotag in the autotransporter expression cassette.

Characterization of the minicell production phenotype. We identified production of minicells by the wild type and genome reduced E. coli strains by cryo electron microscopy (cryoEM). FIG 2 shows the results of the cryoEM experiments. We found 160 that we were able to produce minicells from the parental wild type strain (ME 5000), and from each of the highly deleted strains ME 5010 (2.4% deleted), ME 5119 (15.8% deleted) and ME 5125 (29.7% deleted), with the production of purified minicells after a differential centrifugation procedure. The cryoEM studies confirmed the presence of mostly minicells in the purified minicell preparation. In this report we will focus on a 165 comparison of the non-deleted ME 5000 strain and the 29.7% deleted ME 5125 strain.

Image cytometry also confirmed production of minicells from both the wild type and deleted strains (see Fig. 4 

Expressing recombinant proteins in the cytoplasm and on the surface of minicells made from genome reduced E. coli. Minicells made from genome reduced E. coli will 170 likely have many uses, among the most important of these will be the production of minicells encapsulating biotechnologically useful proteins either in their cytoplasm or on their surfaces. To show that minicells made from genome reduced bacteria can contain recombinant proteins within their cytoplasm, we transformed the minCminD mutants of the wild type (ME5000) and the most highly genome reduced strain of E. coli in the 175 TMUG collection (ME5125) 4, 5 with a GFP expressing plasmid, pMP2463 26 . We also transformed the undeleted ME 5000 and 29.7% deleted ME 5125 stains with minCminD mutations with pRAIDA2, the plasmid that expresses an HA immunotag via an AIDA-I autotransporter surface expression cassette under the control of a rhamnose-inducible promoter 25 . 180

To determine relative amounts of recombinant protein in the minicells and parental cells, we conducted immunoblots on protein extracts made from the minicells and from the parental cells used to produce the minicells, interrogating the immunoblots with antibodies directed against either GFP expressed in the cytoplasm or the HA immunotag expressed on the surface of the cells, normalizing the signal attributable to 185 the recombinant protein to a standard, the bacterial chaperone DNAK.

FIG 3 shows GFP and HA expression in the wild type and minCminD mutant ME5000 and genome reduced ME5125 E. coli strains as assessed by the immunoblots using antibodies against GFP and HA. We found that the GFP was present in both the parental cells and in minicells (FIG 3A) , and that the normalized amount of GFP was 190 enriched 8.7-fold in the minicells made from ME 5000, 2.3-fold in the minicells made from ME 5125 (FIG 3C) . We also found that AIDA-I autotransporter-expressed HA immunotag was present in protein extracts made from the parental cells and the minicells (FIG 3B and FIG 3C) . The HA immunotag placed into the minicells also appeared to be concentrated in the minicells. We found that HA was present in the 195 minicells and was enriched 2.0 fold in the minicells made from ME 5000 and 1.9-fold in the ME5125 genome reduced bacteria. To analyze the data from the immunoblot experiment, we log-transformed the normalized densitometric data and compared the expression of GFP or HA in the minicells with the parental cells. The enrichments were statistically significant for the ME 5000 and ME 5125 cells expressing GFP or HA (p 200 <0.01), by ANOVA analysis of the independently conducted immunoblot experiments .

Image cytometry analysis of non-genome reduced and genome reduce bacteria expressing GFP and HA. To further evaluate the expression of cytoplasmic-and surface-expressed recombinant proteins in non-genome reduced and genome reduced bacteria with minCminD mutations, we conducted a series of image cytometry studies. 205

We imaged the bacteria, selecting images that the show bacteria with and without a budding phenotype (FIG 4) . Here we show the images from the highly-deleted ME 5125 strain. The images show that GFP is expressed in the cytoplasm and that the GFP is also present in buds at the poles of the bacteria. The images further show that HA tends to be concentrated at the poles of the bacteria, as had been described previously for 210 wild type E. coli 21 scatter (minicells) to high scatter (parental cells) was 1.2 for the GFP-expressing ME 5000 cells, 1.3 for the GFP-expressing ME 5125 cells, 1.2 for the HA-expressing ME5000 cells, and 1.5 for the HA-expressing ME 5125 cells. The difference between the Signal Intensity/Area values between low and high scatter populations for both the GFP-and HA-expressing ME 5000 and ME 5125 cells was significant (p <0.001, two-235 tailed t-test).

To confirm that the recombinant GFP protein and the HA immunotag expressed via the AIDA-I autotranporter are present in the minicells isolated from the minCminD mutants of the undeleted ME 5000 strain and the 29.7% genome-reduced ME 5125 strain, we conducted additional image cytometry experiments on minicells isolated from 240 the bacteria using a differential centrifugation procedure. Here we show that mutating minC and minD in GR E. coli strains produce 245 minicells. Moreover, recombinant proteins can be successfully expressed in the genome-reduced cells, and concentrated in, and on, minicells derived from these genome-reduced E. coli. This demonstration can inform the use of minicells made from genome reduced E. coli in ways useful for basic investigations, bioindustry, and biomedicine. Additional advantages of a GR minicell may include improved cryo-EM 250 structural studies due to fewer bacterial structures in the minicells as well as fewer genes that engage in metabolic activities not absolutely essential for metabolism, growth, and replication.

Bacteria are increasingly being metabolically engineered to more efficiently produce specific, industrially useful molecules (reviewed in 27 ). Unneeded bacterial 255 metabolic pathways may divert substrates to non-useful pathways and/or produce unwanted side products. If minicells are used to package recombinant proteins or metabolic products made in engineered bacteria, using minCminD strains of genome reduced, engineered bacteria may be helpful.

Expressing recombinant proteins on the surfaces of bacteria using 260 autotransporters can be a convenient way to express and purify proteins with limited solubility. Since translation and export to the bacterial surface is very tightly coupled, recombinant low solubility proteins are placed on the surface very soon after translation so they do not have an opportunity to form insoluble aggregates or inclusion bodies within the bacterial cell [17] [18] [19] . Expressing recombinant proteins in genome reduced 265 bacteria , followed by concentration in, or on, minicells may make this easier.

We demonstrated that both the cytoplasmically expressed protein GFP and AIDIA-I autotransporter-mediated HA immunotag were concentrated in the minicells. may be helpful to consider that while the bacterial cytoplasm is sometimes thought of as being homogeneous, in fact it is not. The bacterial chromosome, and its associated proteins and structures, occupy a volume within the bacteria, so minicell cytoplasm is essentially derived from chromosome-free volume of the bacterial cytoplasm, where GFP may be present in higher abundance. Minicells may therefore be a means to 285 enhance the relative amounts of bacterial non-chromosome-associated cytoplasmic proteins for bioindustrial processes.

One of the important uses proposed for minicells has been as antigen delivery vehicles for new vaccines 15, 16 . No clinically approved vaccines have yet been produced using minicells, but it is plausible to hypothesize that a minicell with a surface-expressed 290 vaccine antigen may be a more effective immunogen than a recombinant bacteria expressing the same antigen on its surface. An antigen expressed on the bacterial surface using a Gram-negative autotransporter would be more concentrated on the minicell. Minicells made from genome reduced bacteria would also include fewer host In summary, we show here that minicells can be produced from highly genomereduced E. coli, and that recombinant proteins are concentrated in the cytoplasm and on the surfaces of the minicells. Such minicells from GR bacteria may prove useful for a 310 variety of biotechnological applications.

Bacteria, minC and minD mutants. The deleted bacterial strains with different 315 percentages of the bacterial genome deleted were the kind gift of J. Kato 4, 5 

Metropolitan University, Tokyo, Japan. The National Bioresource Project, E. coli Strain Office, National Institute of Genetics, Japan, provided the E. coli strains used in this study, derivatives of MG1655, include ME 5000 (with 0% of the genome deletedreference wild type), ME 5010 (2.4% deleted), ME 5119 (15.8% deleted) and ME 5125 320 (29.7% deleted). Strains were grown in Luria-Bertani (LB) media and on LB agar plates, with the appropriate antibiotics as needed. Expression plasmid transformation. To prepare competent cells, bacteria were grown overnight at 37 C, shaking, in LB broth. LB broth was inoculated from overnights and grown to log phase. Cells were made electrocompetent as described above and transformed via electroporation with pMP2463 or pRAIDA2. Electroporation was conducted in 0.1 cm electroporation cuvettes with the Gene Pulser Xcell electroporation 405 system (Bio-Rad) and pulsed at the following settings: 1800 V, 25µF, and 200 Ω.

Electroporated cells were immediately transferred to 10 ml tubes with 1mL of SOC media (Life Technologies), and grown at 37 C for 1 hour before plating on LB agar plates containing the appropriate antibiotic.

Minicell purification and characterization. Minicells were produced as described 33 410 with modifications. A 3-5 ml miniprep culture of engineered bacteria was initiated from a glycerol stock or from a colony grown on fresh plate. The culture was grown at 37 C for 6-8 hours or overnight (in the case of ME5125 strain) and expanded to 50 ml culture growing overnight at 37 C. Next morning, this culture was used to start 1-2 liter culture which was grown 20-24 hours at 37 C with half of the usual antibiotic concentration. If 415 required, the surface expression of the HA epitope was induced in the cells transformed with pRAIDA2 with rhamnose added to 0.5 mM added at the start of 1-liter minicells maxiprep.

Bacteria were separated from minicells by centrifugation 10 min at 4000 x g; supernatant was subjected to 10000 x g, 12 min centrifugation to sediment minicells. 420

Minicell pellet was resuspended in 10-15 ml PBS and subjected to two subsequent 3000 x g, 10 min centrifugations to pellet residual bacteria. As the final step, to wash minicells from bacterial growth media, their volume was increased to 50 ml and minicells were spun down 10000 x g, 25 min at 15C. The final minicell pellet was resuspended in PBS and stored at -20C. The characteristics and quality of the minicell 425 preparations were verified by dynamic light scattering and cryo-EM.

Electron microscopy. The size and morphology of minicells were measured using a FEI Tecnai F20 (FEI, Hillsboro, OR) transmission electron microscope operating at 120 kV cryo-Electron microscopy (cryo-EM). The cryo-EM samples were prepared by a standard vitrification method. An aliquot of ~3 μl sample solution was applied onto a 430 glow-discharged perforated carbon-coated grid, (2/1-3C C-Flat; Protochips, Raleigh, NC, USA) and the excess solution was blotted with filter paper. The samples were then quickly plunged into a reservoir of liquid ethane at -180 C. The vitrified samples were stored in liquid nitrogen and transferred to a Gatan 626 cryogenic sample holder (Gatan, Pleasantville, CA) and then maintained in the microscope at -180°C. All Images 435 were recorded with a Gatan 4K x 4K pixel CCD camera under cryo-condition at a magnification of 9600X or 29,000X with a pixel size of 1.12nm or 0.37 nm, respectively, at the specimen level, and at a nominal defocus ranging from -1 to -3 μm. The unfiltered samples were recorded at 9600X, images were recorded with a 500nM magnification bar, filtered samples were recorded at 29,000X, and images were recorded with a t 440 100nM magnification bar. Imagestream acquisition was set to collect 20,000 bacteria per sample. Objects were analyzed using IDEAS software 6.2.64.0. Focused bacteria were gated using the Gradient_RMS parameter for the brightfield channel. Single bacteria were then gated using the Aspect Ratio and Area parameters. Minicells were gated by Scatter and 495 GFP/Alexa 488 signal intensity to distinguish whole rod, shaped bacteria from minicells.

Statistical and data analysis. Data was analyzed with SAS 9.4 and R (v1.3.1093) with the Rstudio environment with included packages, and the tidyverse and stats packages, with visualization using ggplot2. The Western blot experiments were analyzed as randomized block experiments, using two-way ANOVA with no interaction. 500

Data were transformed to the log scale to better meet the assumptions underlying ANOVA and to facilitate interpretations as fold change. cassette. Of note, similarly to data previously described 21 , for experiments involving the AIDA-I-expressed HA immunotag, the signal due to the autotransporter-expressed HA immunotag, concentrates at the poles of the bacteria (B), and then in these minCminD minicell producing mutant bacteria, appears to be further concentrated in the budding 550 structures at the bacterial poles that are the precursors to minicells (D). D. Image cytometry analysis of ME 5125 minCminD without an expressing plasmid. E.

Image flow analysis of ME 5125 minCminD expressing GFP. F. Image cytometry analysis of ME 5125 minCminD expressing HA on the bacterial surface. G. The ratio of 560 the signal intensity from the fluorescence due to the recombinant protein GFP to the area of the gated particle ("Hi scatter" for the elongated bacteria, "Lo scatter" for the small, close-to-spherical mincells) in the preparation (arbitrary units), which contains both bacteria and derived minicells, for either the undeleted ME 5000 minCminD bacteria or the 29.7% deleted ME 5125 minCminD bacteria, as indicated. H. The ratio of 565 the signal intensity from the fluorescence due to the recombinant HA protein to the area of the gated particle ("Hi scatter" for the elongated bacteria, "Lo scatter" for the small, close-to-spherical mincells) in the preparation (arbitrary units), which contains both bacteria and derived minicells, for either the undeleted ME 5000 minCminD bacteria or the 29.7% deleted ME 5125 minCminD bacteria, as indicated. 570 

On the road to synthetic life: the minimal cell and genome-scale engineering

How to make a minimal genome for synthetic minimal cell

Construction of a minimal genome as a chassis for synthetic biology

Construction of consecutive deletions of the Escherichia coli chromosome

Cell size and nucleoid organization of engineered Escherichia coli cells with a reduced genome

Minicells, Back in Fashion

MINIATURE escherichia coli CELLS DEFICIENT IN DNA

Cytoplasmic RNA Polymerase in Escherichia coli

Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics

How Bacteria Assemble Flagella

Three-Dimensional Model of <em>Salmonella</em>'s Needle Complex at Subnanometer Resolution

The Bacteriophage T7 Virion 610 Undergoes Extensive Structural Remodeling During Infection

Icosahedral bacteriophage ΦX174 forms a tail for DNA transport during infection

Structural remodeling of bacteriophage T4 and host membranes during infection initiation

Immune responses elicited by bacterial minicells capable of simultaneous DNA and protein antigen delivery

Bacterial minicells could offer safer vaccines

The autodisplay story, from discovery to biotechnical and 625 biomedical applications

Type V Secretion Systems: An Overview of Passenger Domain Functions

Interaction of an autotransporter passenger domain with BamA during its translocation across the bacterial outer membrane

Polar localization of the autotransporter family of large bacterial 635 virulence proteins

One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products

Antibiotic marker modifications of lambda Red and FLP helper plasmids, pKD46 and pCP20, for inactivation of chromosomal genes using PCR products in multidrugresistant strains

Cloning and expression of an adhesin (AIDA-I) involved in diffuse adherence of enteropathogenic Escherichia coli

Killed whole-genome reduced-bacteria surface-expressed coronavirus fusion peptide vaccines protect against disease in a 650 porcine model

Use of green fluorescent protein color variants expressed on stable broad-host-range vectors to visualize rhizobia interacting with plants

Metabolic engineering of Escherichia coli and Corynebacterium glutamicum for biotechnological production of organic acids and amino acids

The Euvichol story -Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships

Transformation of Competent Bacterial Cells: Electroporation. In eLS

Molecular Cloning: A Laboratory Manual

Structures and functions of autotransporter proteins in microbial pathogens

Generation of Minicells from an Endotoxin-Free Gram-Positive Strain Corynebacterium glutamicum

Figure 1

Infectious Disease Laboratory, and institutional support for the University of Virginia Flow Cytometry Core Facility.